Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
Yellow Fever01:18

Yellow Fever

Yellow fever is a viral hemorrhagic disease caused by the yellow fever virus (YFV), a member of the Flaviviridae family. It is transmitted primarily by Aedes and Haemagogus mosquitoes in tropical and subtropical regions of Africa and South America. After transmission through a mosquito bite, the virus initially replicates in skin-resident immune cells such as dendritic cells and macrophages. These cells then migrate to the lymph nodes, where viral replication increases, eventually leading to...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Role of HBV genotype, monitoring, and events after cessation of nucleos(t)ide analogue therapy.

Journal of hepatology·2026
Same author

Nucleos(t)ide analogue therapy for EASL immune-tolerant phase hepatitis B.

Gut·2025
Same author

Letter to the Editor: HBV DNA level of genuine immune-tolerant patients.

Hepatology (Baltimore, Md.)·2025
Same author

Perspectives on the Issues of Indeterminate/Gray Zones of Chronic Hepatitis B Virus Infection.

Gastroenterology·2025
Same author

Switching to Entecavir >3 Months Before the End of Tenofovir-Based Therapy in Hepatitis B e Antigen-Negative Patients May Reduce Early Relapse and Hepatitis Flare.

The American journal of gastroenterology·2025
Same author

Letter: No Biochemical Relapse Is Associated With the Highest Off-Therapy HBsAg Loss Rate.

Alimentary pharmacology & therapeutics·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jun 25, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

La infección por el virus de la hepatitis B infección por el virus de la hepatitis B.

Yun-Fan Liaw1, Chia-Ming Chu

  • 1Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.

Lancet (London, England)
|February 17, 2009
PubMed
Resumen
Este resumen es generado por máquina.

Las tasas de infección por hepatitis B han disminuido debido a las vacunas, pero los casos crónicos persisten. Los tratamientos actuales suprimen el virus, pero rara vez lo eliminan, lo que hace necesario el desarrollo de nuevos fármacos para obtener mejores resultados.

Más Videos Relacionados

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Videos de Experimentos Relacionados

Last Updated: Jun 25, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Área de la Ciencia:

  • Hepatología Hepatología.
  • Virología Virología.
  • Inmunología Inmunología.

Sus antecedentes:

  • La infección por hepatitis B sigue siendo un importante problema de salud mundial, que afecta a más de 350 millones de personas en todo el mundo.
  • La infección crónica por hepatitis B plantea riesgos para enfermedades hepáticas graves como la cirrosis y el carcinoma hepatocelular.
  • La replicación del virus de la hepatitis B (VHB) se reconoce como un factor primario en el daño hepático impulsado por el sistema inmunológico y el avance de la enfermedad.

Objetivo del estudio:

  • Revisar el panorama actual del tratamiento de la hepatitis B.
  • Para resaltar las limitaciones de las terapias existentes, incluida la resistencia a los medicamentos.
  • Hacer hincapié en la necesidad de nuevas estrategias terapéuticas y el desarrollo de fármacos.

Principales métodos:

  • Revisión de la literatura científica sobre virología, inmunología e historia natural de la hepatitis B.
  • Análisis de la eficacia y los inconvenientes de los tratamientos antivirales actuales.
  • Discusión de las tendencias emergentes y las direcciones futuras en la terapia de la hepatitis B.

Principales resultados:

  • Las terapias antivirales, incluidos el interferón y los análogos nucleósidos / nucleótidos, suprimen efectivamente la replicación del VHB y detienen la progresión de la enfermedad.
  • Los tratamientos actuales rara vez logran la eliminación completa del virus.
  • La resistencia a los medicamentos es un desafío significativo en el manejo a largo plazo de la hepatitis B.

Conclusiones:

  • A pesar de los avances, la hepatitis B crónica sigue siendo un complejo desafío para la salud mundial.
  • Los tratamientos existentes suprimen pero no curan la hepatitis B, lo que lleva a una resistencia potencial.
  • La investigación y el desarrollo de nuevos fármacos y estrategias terapéuticas son cruciales para mejorar los resultados de los pacientes y lograr el aclaramiento viral.